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Abstract
The aim of this study was to determine the effect of obesity on recurrence time in ovarian cancer. This was a
multicenter, retrospective chart review of 370 patients. The median time to recurrence was 15 months in obese
and nonobese patients. Obesity does not affect the time to recurrence or progression-free survival in patients
with ovarian cancer.
Introduction/Background: The objective of this study was to examine whether obesity affects the time to recurrence
in primary epithelial ovarian cancer. Patients and Methods: A multicenter retrospective chart review was performed
between 2004 and 2009. Three hundred seventy patients were eligible for analysis. Demographic and clinicopatho-
logical variables and treatment-related data were collected. Women with a body mass index (BMI) > 30 were cate-
gorized as obese. The time to recurrence was quantiﬁed in terms of months. Survival analyses were performed using
the Kaplan-Meier method and compared using log-rank testing. Results: One hundred thirty (35%) obese patients
were compared with 240 (65%) nonobese patients. A recurrence was documented in 125 (47.9%) nonobese patients
and 49 (37.7%) obese patients. Time to recurrence between both BMI groups was identical, at 15 months (P ¼ 1.0).
The progression-free survival was similar in obese and nonobese subjects (P ¼ .118). Conclusion: Obesity does not
affect the recurrence time in patients with primary ovarian cancer.
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The prevalence of obesity in adults in the United States is
35.6%.1 This condition has been associated with an increased risk
of several types of cancers, including breast and ovarian cancer, and
research indicates that obesity contributes 14% to 20% of cancer-
related mortality.2 Ovarian cancer is the ﬁfth leading cause of
cancer deaths in women according to cancer statistics reported by
the American Cancer Society in 2012. This accounts for 6% of
cancer related deaths in women.3 Approximately 12% of patients
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http://dx.doi.org/10.1016/j.cogc.2014.02.002of patients with advanced ovarian epithelial cancer will develop
recurrent disease after initial diagnosis treatment.5 Management of
ovarian cancer is highly dependent on response to degree of tumor
debulking6 and chemotherapy7; modiﬁable prognostic factors are
limited.8 Obesity is a common and potentially modiﬁable prog-
nostic factor.
Obesity affects the body’s hormonal balance. Ovarian cancer has
been shown to have some degree of hormonal responsiveness.9
There is clinical and biochemical evidence supporting the thera-
peutic role of hormonal agents in ovarian cancer treatment such as:
tamoxifen,10 aromatase inhibitors,11 gonadotropin modulators,12
and progestins.13 In addition, Risch documented abnormal
androgen homeostasis in ovarian cancer.14 Obesity represents a
hyperandrogenic and hyperestrogenic state. Increased peripheral
production of androgens and estrogens in adipose tissue and
decreased sex hormone-binding globulin results in increased free
testosterone and estrone. Additionally, adipose tissue concentrates
lipid-soluble steroids, contributing to increased androgen clearance
and an extremely enlarged total body steroid pool.15 Li et al16 hy-
pothesized that hyperandrogenism mediated by obesity in the
presence of certain androgen receptor polymorphisms might pro-
mote aggressive epithelial ovarian cancer biology.Clinical Ovarian and Other Gynecologic Cancer December 2013 - 31
Figure 1 Study Population With Exclusions
* These 99 patients who progressed or had persistent disease while receiving adjuvant
chemotherapy were excluded from the primary analysis because they had no disease-free
interval, so time to recurrence could not be deﬁned, which was our primary outcome. They
were analyzed separately and there was no difference in the proportion of obese patients when
compared with the study population (P ¼ .88).
Obesity and Time to Recurrence in Ovarian Cancer
32 -Few studies have examined obesity as a prognostic factor for time
to recurrence in ovarian cancer.6,7,17-20 Thus, the primary aim of
this study was to investigate the relationship between obesity and
progression-free survival among a cohort of women diagnosed with
ovarian cancer. It was hypothesized that obese ovarian cancer pa-
tients would have greater rates of recurrence compared with non-
obese patients.
Patients and Methods
A multicenter retrospective study was performed at Mercy
Medical Center in Baltimore, Maryland and University of Michigan
Medical Center in Ann Arbor, Michigan, on all patients with pri-
mary epithelial ovarian cancer diagnosed between 2004 and 2009
(n ¼ 591). The study was approved by the Institutional Review
Board at both institutions.
All data were abstracted from the patient’s medical records.
Preoperative height and weight data were collected from medical
charts, measurements within 1 month after surgery were also
permissible if preoperative values were not available. Body mass was
calculated and patients were categorized according to their body
mass index (BMI) based on the deﬁnitions set forth by the Classi-
ﬁcation of Overweight and Obesity by BMI (World Health Orga-
nization, 2004).21 Patients were classiﬁed as obese if they had a
BMI  30, or nonobese if they had a BMI < 30.
Abstracted covariates included age, medical comorbidities, stage,
and histology. Preoperative comorbidity data collected included:
hypertension, diabetes, coronary heart disease, and pulmonary dis-
ease such as asthma or chronic obstructive pulmonary disease.
Treatment-related data such as number of cycles of adjuvant
chemotherapy, and optimal versus suboptimal tumor debulking,
were also collected. Optimal debulking was deﬁned as the presence
of residual implants < 1 cm, in accordance with the deﬁnition
set forth by the Gynecologic Oncology Group.22 The diagnosis of
recurrence was made according to positive clinical, radiologic, or
serologic evidence of recurrence. Time to recurrence was then
quantiﬁed in terms of months from initial surgery.
Patients who did not have a complete clinical, radiological, and
serologic response to surgical debulking and adjuvant chemotherapy
were classiﬁed as having persistent or progressive disease and
were excluded from this analysis [n ¼ 99]. In addition, patients who
died after surgery, before adjuvant chemotherapy treatment was
completed, those who were lost to follow-up, or had missing
requisite data to determine the diagnosis of recurrence or a disease-
free interval were also excluded from the analysis. Patients with
synchronous tumors were also excluded. Those without data sufﬁ-
cient to calculate BMI or for whom follow-up data were not
obtainable from the chart were also excluded from review. Patients
who received neoadjuvant chemotherapy were also excluded, to
maintain homogeneity of the sample population.
Differences in the characteristics between BMI groups were
analyzed using c2 test and Fisher exact test for categorical variables.
Continuous variables were analyzed using Student t test, and Mann-
Whitney U test. The Kolmogrov-Smirnov method was used for
testing normality. Kaplan-Meier curves with log-rank testing were
used for survival analysis. Multivariate models were assessed using
Cox regression. All statistical analyses were performed using Stata
Software (version 12, College Station, TX).Clinical Ovarian and Other Gynecologic Cancer December 2013Results
Five hundred ninety-one persons were diagnosed with primary
epithelial ovarian cancer and treated between 2004 and 2009 at
both institutions. Of those, 16.8% (n ¼ 99) had persistent or
progressive disease, 11% (n ¼ 65) had missing requisite data, 3.2%
(n ¼ 19) had synchronous tumors, 6% (n ¼ 36) underwent neo-
adjuvant chemotherapy, and 2 patients died shortly after surgery.
The remaining sample size was n ¼ 370 (Fig. 1).
Three hundred seventy patients who met the inclusion criteria
were identiﬁed. Demographic and clinicopathological data of the
population are shown in Table 1. Approximately 35%, n ¼ 130 of
the patients were classiﬁed as obese. Obesity did not vary by age or
race (P ¼ .46 and .57, respectively). Most patients were diagnosed
at stage III (51.6%, n ¼ 191), and histology was predominantly
papillary serous (51%, n ¼ 189). Neither stage nor histologic
subtype varied according to obesity (P ¼ .6 and .21, respectively).
Pulmonary disease, hypertension, and diabetes were more prevalent
in the obese population (P ¼ .03, .001, and < .001, respectively).
Treatment for obese and nonobese patients was similar. Most
received optimal debulking (70%, n ¼ 259) and had 6 or more
cycles of standard adjuvant chemotherapy (71%, n ¼ 261).
Treatment data are given in Table 2. Of the patients whose disease
recurred in the study population; there was no difference in the
platinum sensitivity between obese and nonobese patients (83.3%
vs. 77.3%; P ¼ .633).
The progression-free survival curves for both patient groups were
similar (P ¼ .11). There was no difference in the incidence of
recurrence between nonobese and obese patients (47.9% vs. 37.7%;
Table 1 Patient Demographic and Clinicopathological Factors
Stratiﬁed According to BMI
Factor
BMI <30
(n [ 240)
BMI ‡30
(n [ 130) P a
BMI Range 15-29 30-66
Mean Age (SD), Years 58.2 (12.2) 57.3 (10.5) .463
Race, n (%) .573
Nonwhite 20 (8.3) 13 (10.0)
White 220 (91.7) 117 (90.0)
Stage, n (%)b .607
I 54 (22.5) 32 (24.6)
II 36 (15.0) 23 (17.7)
III 125 (52.1) 66 (50.8)
IV 21 (8.8) 7 (5.4)
Unstaged 4 (1.7) 2 (1.5)
Grade, n (%) .846
1 29 (12.1) 20 (15.4)
2 34 (14.2) 18 (13.8)
3 122 (50.8) 64 (49.2)
Missing 55 (22.9) 28 (21.5)
Histology, n (%) .214
Serous 133 (55.4) 56 (43.1)
Clear cell 9 (3.8) 11 (8.5)
Endometrioid 38 (15.8) 20 (15.4)
Mucinous 21 (8.8) 19 (14.6)
Mixed 8 (3.3) 4 (3.1)
Other 17 (7) 13(10)
Undifferentiated 14 (5.8) 7 (5.4)
Pulmonary Disease, n (%) .030
Yes 9 (3.8) 12 (9.2)
No 231 (96.3) 118 (90.8)
Hypertension, n (%) .001
Yes 77 (32.1) 66 (50.8)
No 163 (67.9) 64 (49.2)
Coronary Heart Disease, n (%) .141
Yes 14 (5.8) 13 (10.0)
No 226 (94.2) 117 (90.0)
Diabetes, n (%) <.001
Yes 14 (5.8) 31 (23.8)
No 226 (64.2) 99 (76.2)
Abbreviations: BMI ¼ body mass index, calculated as weight (kg)/height (m2); FIGO ¼ Inter-
national Federation of Gynecology and Obstetrics.
aSigniﬁcance P < .05. P was calculated using c2 and Fisher exact test, and Student t test
where appropriate.
bStages I to IV according to the FIGO staging system.
Table 2 Surgical Outcomes Stratiﬁed According to BMI
Variable
BMI <30
(n [ 240)
BMI ‡30
(n [ 130) P a
Number of Chemotherapy
Cycles, n (%)
.469
<6 44 (68.8) 20 (31.3)
6 166 (63.6) 95 (36.4)
Missing 30 (66.7) 15 (33.3)
Debulking Status, n (%) .663
Optimal 169 (70.4) 90 (69.2)
Suboptimal 55 (22.9) 28 (21.5)
Missing 16 (6.7) 12 (9.2)
Abbreviation: BMI ¼ body mass index, calculated as weight (kg)/height (m2).
aSigniﬁcance P < .05. P was calculated using c2 and Fisher exact test, and Student t test
where appropriate.
Table 3 Recurrence Data According to BMI
Variable
BMI <30
(n [ 240)
BMI ‡30
(n [ 130) P
Recurrence, n (%) .118a
Yes 115 (47.9) 49 (7.7)
No 125 (52.1) 81 (62.3)
Median Recurrence
Time (IQR), Months
15 (10) 15 (17) .987b
Abbreviation: BMI ¼ body mass index, calculated as weight (kg)/height (m2); IQR ¼ interquartile
range.
ac2 test.
bMann-Whitney U test.
Karina E. Hew et alP ¼ .06). Median time to recurrence was 15 months in both groups
(P ¼ 1.0). Recurrence data are shown in Table 3 and survival curves
are given in Figure 2.
There were no differences in the time to recurrence or
progression-free survival when BMI was subclassiﬁed into under-
weight, normal, overweight, and obese (classes I, II, and III)
in accordance with the WHO 2004 criteria.21 A multivariate
model including pulmonary disease, hypertension, and diabetes, thecovariates that were signiﬁcantly different according to obesity
status, was explored using Cox regression. However, these cova-
riates had no statistically signiﬁcant effect on differences in recur-
rence and substantive ﬁndings remained unchanged. Further and
additional Cox regression analysis was performed adjusting for
International Federation of Gynecology and Obstetrics stage,
debulking status, and BMI, which showed no difference in the time
to recurrence.
Discussion
The effect of obesity on survival in ovarian cancer has been
investigated in other studies with conﬂicting results.6,7,17-20
Pavelka et al noted a shorter time to recurrence in obese patients.
However, this study was limited by the sample size, which con-
sisted of 31 patients with a BMI of  30.18 In their study, Mat-
thews et al found a statistically signiﬁcant decrease in the rate
of recurrence in obese patients (68% vs. 79%; P ¼ .04) and
no difference in progression-free survival (17 vs. 11 months;
P ¼ .14). This study had a larger sample size consisting of
304 patients with 71 obese patients. They concluded that obesity
did not have an effect on time to recurrence when patients were
optimally debulked.6 Barrett et al investigated progression-free
survival and overall survival in 1067 patients who participated in
the SCOTROC 1 (Scottish Randomized Trial in Ovarian Cancer
1) trial. There were 130 obese patients in this population which is
comparable with our sample size. They concluded that obesityClinical Ovarian and Other Gynecologic Cancer December 2013 - 33
Figure 2 Progression-Free Survival
Obesity and Time to Recurrence in Ovarian Cancer
34 -was not associated with a poorer prognosis in patients who received
chemotherapy based on their measured glomerular ﬁltration
rate and actual body weight.7 The patients in our study received
chemotherapy doses based on their actual body weight and the
doses were not capped. This approach has been found to be safe
and efﬁcacious in obese patients with other cancers.23 It was also
recently reinforced according to the most recent guidelines put
forth by the American Society of Clinical Oncology. These
guidelines state that ideal body weight should be used to calculate
the appropriate chemotherapy doses in obese patients.24 A Swedish
study by Skirnisdottir and Sorbe19 had a large sample size of
635 patients with 75 obese patients. This study showed no sig-
niﬁcant differences in recurrence-free survival across all BMI sub-
groups. The 5-year recurrence-free survival of the complete series
was 72%. However, this study investigated patients at only early-
stage epithelial ovarian cancer despite the fact that most patients
present with advanced-stage disease. A more recent study by
Skirnisdottir and Sorbe showed that patients who were under-
weight with serous histology had poorer survival outcomes.20
Our study consisted of 370 patients with primary ovarian cancer,
130 of whom were obese. There was no statistical difference noted
in demographic or clinicopathological factors between obese and
nonobese subjects. However, there was a high prevalence of medical
comorbidities in the obese group, which was expected because
obesity is a well established risk factor for these medical conditions
related to obesity. Results of this study showed that there was no
statistically signiﬁcant difference in the disease-free interval or
progression-free survival between obese and nonobese patients. It is
important to note that we intentionally excluded patients with
persistent or progressive disease, because we were speciﬁcally
investigating the time to disease recurrence and progression-free
survival in obese patients with ovarian cancer. To evaluate these
parameters, the patients who showed any evidence of residual
disease based on clinical, radiological, or serological data after sur-
gical staging and standard adjuvant chemotherapy were excluded
from the study. We acknowledge that this would be a useful data
set to investigate in evaluation of overall survival in this patient
population.Clinical Ovarian and Other Gynecologic Cancer December 2013In a review article, Risch concluded that there was evidence sup-
porting the role of androgens and progesterone in etiology of ovarian
cancer.14 Obesity is thought to result in a hyperandrogenic state.15
Lipid-soluble hormones such as androgens, estrogens, and proges-
terone are sequestered in adipose tissue, signiﬁcantly increasing the
total body steroid pool. There is also some evidence to suggest that
there is an upregulation of adrenocortical steroidogenesis resulting in
increased androgen secretion in obese subjects.15 Li et al16 reported
that hyperandrogenism mediated by obesity in the presence of
certain androgen receptor polymorphisms might promote aggressive
epithelial ovarian cancer biology. Obesity has been shown to be an in
important risk factor in tumor carcinogenesis in several types of
cancers.25 However, no deﬁnitive humoral etiology has been estab-
lished for ovarian cancer, unlike endometrial cancer, which has a well
established hormonal etiology.26 Findings from this study do not
give clinical support to the fact that tumor biology is negatively
affected by the hormonal changes related to obesity.
The strengths of our study include the large overall sample size,
and one of the largest populations of obese patients who have
been investigated in examination of the effect of obesity on the
time to disease recurrence in primary epithelial ovarian cancer.
The population was very homogenous and stringent exclusion
criteria were used. In this study, we investigated a broader pop-
ulation of ovarian cancer patients, including all stages of cancer.
Weaknesses include that this was a retrospective study. Also, BMI
was calculated at the time of diagnosis and presentation to the
gynecologic oncologist, which would take into account ascites as
part of body weight. Other studies have used BMI at the time of
postoperative visit18 or the time of administering the ﬁrst cycle of
adjuvant chemotherapy.7
Conclusion
Our ﬁndings suggest that obesity does not affect the time to
disease recurrence or progression-free survival in patients with
ovarian cancer. These clinical ﬁndings are in keeping with other
large studies that have investigated this hypothesis. However, other
modiﬁable prognostic factors such as metformin and its effect
on ovarian cancer tumor biology and survival are currently being
researched.27,28 Future studies include investigating a subset of
obese patients who are taking metformin to evaluate their survival
outcomes. Also, performing a metaanalysis of the existing data on
obesity as a prognostic factor in ovarian cancer, because of the
conﬂicting outcomes and relatively small sample sizes of the studies,
should be done.Clinical Practice Points
 Ovarian cancer is ﬁfth leading cause of cancer deaths in women
in the United States.
 Despite many advances in treatment over the past decade
and the incorporation of new targeted therapies, the mor-
tality remains essentially unchanged. Therefore, more studies
have investigated modiﬁable prognostic factors that might
improve treatment response, overall and progression-free
survival.
 The role of obesity as a prognostic factor in ovarian cancer re-
mains largely controversial.
Karina E. Hew et al To our knowledge, this is one of the largest studies to date to
investigate how obesity affects time to disease recurrence and
progression-free survival in ovarian cancer.
 We concluded that despite the laboratory evidence supporting
more aggressive tumor biology related to hormonal changes of
obesity, there was no difference in the time to disease recur-
rence or progression-free survival between obese and nonobese
patients.
 This would suggest that although obesity is related to many
chronic illnesses, ovarian cancer recurrence is not negatively
affected by this condition.Acknowledgments
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